Therapeutic effect of recombinant human growth hormone on children with growth hormone deficiency and different pituitary developmental conditions: a prospective study
WEI Xiu-Fang, ZHANG Yue-Ying, YAN Zhi-Ping, AN Jing
Department of Pediatrics, Xuchang Maternity and Child Health Hospital, Xuchang, Henan 461000, China
Abstract Objective To investigate the therapeutic effect of recombinant human growth hormone (rhGH) on children with growth hormone deficiency (GHD) and different pituitary developmental conditions. Methods A prospective study was performed on 90 children with GHD who were admitted to Xuchang Maternity and Child Health Hospital from June 2020 to December 2021. According to pituitary height on the median sagittal plane, they were divided into three groups: pituitary dysplasia group (n=45), normal pituitary group (n=31), and enlarged pituitary growth group (n=14). The changes in body height, growth velocity, height standard deviation score and serum levels of insulin-like growth factor binding protein-3 (IGFBP-3) and insulin-like growth factor-1 (IGF-1) were examined after treatment in the above three groups, and the differences of the above indices before and after treatment were compared among the three groups. Results After treatment, all three groups had significant increases in body height, growth velocity, height standard deviation score, and the serum levels of IGFBP-3 and IGF-1 (P<0.05). Compared with the normal pituitary group, the pituitary dysplasia group and the enlarged pituitary growth group had significantly higher values in terms of the differences in body height, growth velocity, height standard deviation score, IGF-1, and IGFBP-3 before and after treatment (P<0.05). There was no significant difference in the incidence rate of adverse reactions among the three groups (P>0.05). Conclusions In GHD children with different pituitary developmental conditions, rhGH can promote bone growth and increase body height, especially in children with pituitary dysplasia and pituitary hyperplasia, with good safety.
WEI Xiu-Fang,ZHANG Yue-Ying,YAN Zhi-Ping et al. Therapeutic effect of recombinant human growth hormone on children with growth hormone deficiency and different pituitary developmental conditions: a prospective study[J]. CJCP, 2023, 25(8): 800-804.
WEI Xiu-Fang,ZHANG Yue-Ying,YAN Zhi-Ping et al. Therapeutic effect of recombinant human growth hormone on children with growth hormone deficiency and different pituitary developmental conditions: a prospective study[J]. CJCP, 2023, 25(8): 800-804.
Chinoy A, Murray PG. Diagnosis of growth hormone deficiency in the paediatric and transitional age[J]. Best Pract Res Clin Endocrinol Metab, 2016, 30(6): 737-747. PMID: 27974187. DOI: 10.1016/j.beem.2016.11.002.
Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency[J]. Horm Res Paediatr, 2016, 86(6): 361-397. PMID: 27884013. DOI: 10.1159/000452150.
Amorim PVGH, Grande IPP, Batista RL, et al. Association between KISS1 rs5780218 promoter polymorphism and onset of growth hormone secreting pituitary adenoma[J]. Ann Endocrinol (Paris), 2019, 80(2): 96-100. PMID: 30318257. DOI: 10.1016/j.ando.2018.09.007.
